多种机制有助于多发性骨髓瘤中获得的 TRAIL 耐药性
Fany V Ticona-Pérez1, Xi Chen1, Atanasio Pandiella2,3,4
1Instituto de Biología Molecular y Celular del Cáncer. CSIC-Universidad de Salamanca, Campus Miguel de Unamuno, 37007, Salamanca, Spain.
Cancer cell international
|August 4, 2024
概括
研究人员探索了多发性骨髓瘤细胞如何变得抵抗 TRAIL 诱导的细胞死亡. 关键发现包括死亡受体减少和c-FLIP增加,影响着亡信号和治疗疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 多发性骨髓瘤 (MM) 仍然是一个不可治愈的恶性瘤,尽管最近的治疗进展.
- 向癌细胞死亡途径,如 TRAIL 中介的亡,是MM的有前途的治疗策略.
- 与瘤亡因子相关的诱导亡的配体 (TRAIL) 激活DR4和DR5死亡受体,诱导癌细胞的亡.
研究的目的:
- 为了研究多发性骨髓瘤细胞对 TRAIL 治疗的敏感性.
- 为了生成和描述耐 TRAIL 多发性骨髓瘤模型.
- 阐明多发性髓瘤中 TRAIL 耐药性背后的分子机制.
主要方法:
- 多发性骨髓瘤细胞系对 TRAIL 的敏感性测试.
- 通过连续的 TRAIL 暴露,生成 TRAIL 耐受性的细胞模型.
- 基因组和生物化学分析以确定耐药机制.
- 评估细胞表面受体水平和细胞亡机制的功能.
主要成果:
- 耐 TRAIL 多发性髓瘤细胞显著降低了细胞表面死亡受体水平 (DR4/DR5).
- 损坏的亡机器阻止了在耐药细胞中有效地形成诱导死亡的信号复合体 (DISC).
- 在TRAIL抗性细胞中观察到抑制蛋白c-FLIP的上调.
- 通过操纵受体水平和c-FLIP,可以实现TRAIL灵敏度的部分恢复,但无法恢复完全的灵敏度.
结论:
- 多发性骨髓瘤细胞可以通过死亡受体的下调和c-FLIP的上调来对TRAIL诱导的亡产生抵抗力.
- 这些变化损害了亡信号通路,阻碍了DISC的形成和细胞死亡.
- 其他尚未识别的机制可能有助于多发性髓瘤中TRAIL耐药性,需要进一步调查.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


